International cancer genome characterization efforts have identified several protein phosphatase 2A (PP2A) subunits as recurrently mutated or deleted in human cancers at a higher frequency than originally anticipated. This observation is not surprising since PP2A, the major serine-threonine phosphatase family in human cells, is broadly important in controlling cell signaling and homeostasis and particular PP2A subunits have been shown to act as tumor suppressor genes. However, progress in understanding PP2A has been confounded by the fact that the enzyme exists in at least 80 different isoforms. The study of the interactions of transforming proteins encoded by DNA tumor viruses and host cell proteins has identified many mechanisms that also contribute to the genesis of spontaneously arising cancers. In particular, the SV40 Early Region proteins bind to and inactivate several tumor suppressor gene products including retinoblastoma (RB) and p53. Studies of both SV40 small t antigen (SV40ST) and PyST, which interact with PP2A, have allowed us to begin to see how particular forms of PP2A contribute to tumor suppression. We have previously shown that suppressing particular PP2A subunits phenocopies cell transformation induced by SV40 ST and that these same PP2A subunits are tumor suppressor genes in human cancers. Using newly developed genome scale tools, we have systematically identified the specific PP2A subunits that contribute to cell transformation and have shown that loss of these subunits perturbs three pathways essential for cell transformation (WNT, MYC, AKT). Although these studies have advanced our understanding of how perturbation of PP2A by SV40ST contributes to transformation, we lack a detailed molecular understanding of the molecular connections between PP2A and the pathways essential for cell transformation. We propose to integrate innovative genetic and proteomic technologies to identify substrates and pathways perturbed by tumor suppressor PP2A subunits. In recent work we have found that the STRiatin Interacting Phosphatase And Kinase (STRIPAK) complex not only binds ST-PP2A complexes but is also required for cell transformation induced by altering PP2A function. We hypothesize that ST, or mutations in tumor suppressor PP2A subunits, reprogram the PP2A holoenzyme complex not only by displacing tumor suppressor B subunits but also by modulating the interaction of PP2A with the STRIPAK complex in cancers of both viral and non-viral etiology. In this Project we will use biochemical, genetic and cell biological approaches to understand how PP2A-STRIPAK interactions induce cell transformation to not only enhance our mechanistic understanding of this tumor suppressor family but will also provide new insights into the pathways that help program the malignant state. In addition, these studies will provide a foundation for strategies to target these pathways therapeutically.

Public Health Relevance

The regulation of protein phosphorylation plays key roles in cell physiology and dysregulation of phosphorylation contributes directly to the genesis of diseases such as cancer. In this project, we will use genomic, proteomic and cell biological approaches to understand the role of the PP2A family of serine-threonine phosphatases in human cancers. These studies will not only provide new insights into this tumor suppressor pathway but will also provide new targets with potential for clinical translation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA203655-01A1
Application #
9358182
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tarnita, Roxana M; Wilkie, Adrian R; DeCaprio, James A (2018) Contribution of DNA replication to the FAM111A-mediated simian virus 40 host range phenotype. J Virol :
Kang, Un-Beom; Alexander, William M; Marto, Jarrod A (2017) Interrogating the hidden phosphoproteome. Proteomics 17:
Ni, Jing; Xie, Shaozhen; Ramkissoon, Shakti H et al. (2017) Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19:22-30
Tsherniak, Aviad; Vazquez, Francisca; Montgomery, Phil G et al. (2017) Defining a Cancer Dependency Map. Cell 170:564-576.e16
Hsu, Jessie Hao-Ru; Hubbell-Engler, Benjamin; Adelmant, Guillaume et al. (2017) PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res 77:4613-4625
Becker, Jürgen C; Stang, Andreas; DeCaprio, James A et al. (2017) Merkel cell carcinoma. Nat Rev Dis Primers 3:17077
Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557
Cheng, Jingwei; Park, Donglim Esther; Berrios, Christian et al. (2017) Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathog 13:e1006668
Rouleau, Cecile; Pores Fernando, Arun T; Hwang, Justin H et al. (2016) Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP. J Virol 90:7032-7045
Odajima, Junko; Saini, Siddharth; Jung, Piotr et al. (2016) Proteomic Landscape of Tissue-Specific Cyclin E Functions in Vivo. PLoS Genet 12:e1006429